Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease-related phenotypes in mice can be rescued by blockade of either cellular prion protein or metabotropic glutamate receptor 5. We sought genetic and biochemical evidence that these proteins function cooperatively as an obligate complex in the brain. We show that cellular prion protein associates via transmembrane metabotropic glutamate receptor 5 with the intracellular protein mediators Homer1b/c, calcium/calmodulin-dependent protein kinase II, and the Alzheimer’s disease risk gene product protein tyrosine kinase 2 beta. Coupling of cellular prion protein to these intracellular proteins is modified by soluble amyloid-β oligomers, by mouse brain Alzheimer’s disease transgenes or by human Alzheimer’s disease pathology. Amyloid-β oligomer-triggered phosphorylation of intracellular protein mediators and impairment of synaptic plasticity in vitro requires Prnp–Grm5 genetic interaction, being absent in transheterozygous loss-of-function, but present in either single heterozygote. Importantly, genetic coupling between Prnp and Grm5 is also responsible for signalling, for survival and for synapse loss in Alzheimer’s disease transgenic model mice. Thus, the interaction between metabotropic glutamate receptor 5 and cellular prion protein has a central role in Alzheimer’s disease pathogenesis, and the complex is a potential target for disease-modifying intervention. Cellular prion protein (PrPC) and mGluR5 have both been implicated in Alzheimer’s disease-related phenotypes in mice. Using genetic and biochemical methods, Haas et al. show that direct coupling between PrPC and mGluR5 contributes to Alzheimer’s disease pathology. Partial blockade of this complex has the potential to modify the disease course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Amongst peptide conformations, soluble oligomers of amyloid-b impair synaptic function and can lead to subsequent tauopathy (Lambert et al., 1998; Kayed et al., 2003; Lesne et al., 2006; Shankar et al., 2008; Jin et al., 2011).”
BackgroundRetractedMeta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 2×
“A single nucleotide polymorphism in Pyk2 was recently associated with susceptibility to lateonset Alzheimer’s disease in a genome-wide association study, emphasizing the potential significance of this kinase for Alzheimer’s disease (Lambert et al., 2013; Wang et al., 2015).”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“Amongst peptide conformations, soluble oligomers of amyloid-b impair synaptic function and can lead to subsequent tauopathy (Lambert et al., 1998; Kayed et al., 2003; Lesne et al., 2006; Shankar et al., 2008; Jin et al., 2011).”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“Amongst peptide conformations, soluble oligomers of amyloid-b impair synaptic function and can lead to subsequent tauopathy (Lambert et al., 1998; Kayed et al., 2003; Lesne et al., 2006; Shankar et al., 2008; Jin et al., 2011).”
BackgroundThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 2×
“The metabotropic glutamate recep- tor 5, mGluR5 (encoded by GRM5), is a protein known to provide chronic control over the density and activity of such synapses in a broad range of conditions (Bear et al., 2004).”
BackgroundCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Self-citationLife and Death of Neurons in the Aging Brain
Morrison, J. H., & Hof, P. R. (1997) · Science · doi:10.1126/science.278.5337.412 · Cited by 1,344
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Amongst peptide conformations, soluble oligomers of amyloid-b impair synaptic function and can lead to subsequent tauopathy (Lambert et al., 1998; Kayed et al., 2003; Lesne et al., 2006; Shankar et al., 2008; Jin et al., 2011).”
BackgroundEarly-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654 · cited 1×
“Evidence exists for a genetic interaction between FYN and tau to regulate synapse density and behaviour in APP transgenic mice (Chin et al., 2004, 2005; Roberson et al., 2011).”
BackgroundLu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Self-citationPark, S., Park, J. M., Kim, S., Kim, J.-A., Shepherd, J. D., Smith-Hicks, C. L., Chowdhury, S., Kaufmann, W., Kuhl, D., Ryazanov, A. G., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.023 · Cited by 516
Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468 · cited 3×
“…of mGluR5 function rescues amyloid-b oligomer or APP transgene deficits in synaptic plasticity, synaptic density and memory function in vivo (Renner et al., 2010; Um et al., 2013; Hamilton et al., 2014; Hu et al., 2014). mGluR5 is highly accessible to cytosolic binding partners at its…”
BackgroundInfluentialSynthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466 · cited 2×
“Amyloid-b oligomers bind to PrP with high affinity (Lauren et al., 2009; Balducci et al., 2010; Zou et al., 2011) and multiple studies support a role for PrP in mediating Alzheimer’s disease-related pathology (Lauren et al.”
BackgroundQuantitative assessment of cortical synaptic density in Alzheimer's disease
Scheff, S. W., DeKosky, S. T., & Price, D. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90059-9 · Cited by 446 · cited 4×
“Genetic coupling between Prnp and Grm5 mediates loss of synaptic markers in Alzheimer’s disease model brain in vivo Synapse loss is one of the hallmarks of Alzheimer’s disease that is observable in Alzheimer’s disease transgenic mouse models (Scheff et al., 1990; Jacobsen et al., 2006).”
BackgroundInfluentialMemory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein
Gimbel, D. A., Nygaard, H. B., Coffey, E. E., Gunther, E. C., Laurén, J., Gimbel, Z. A., & Strittmatter, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0395-10.2010 · Cited by 418
Self-citationFyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · cited 1×
“FYN also interacts with tau, such that FYN kinase inhibitors are being examined as agents with disease-modifying action in Alzheimer’s disease (Nygaard et al., 2014, 2015; Kaufman et al., 2015).”
BackgroundSelf-citationNew Concepts in Synaptic Biology Derived from Single-Molecule Imaging
Triller, A., & Choquet, D. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.022 · Cited by 262
The prion protein as a receptor for amyloid-β
Kessels, H. W., Nguyen, L. N., Nabavi, S., & Malinow, R. (2010) · Nature · doi:10.1038/nature09217 · Cited by 253 · cited 1×
“While two studies demonstrated amyloid-b triggered impairment of long-term potentiation (LTP) independently of PrPC (Calella et al., 2010; Kessels et al., 2010), it has been suggested that different conformations of amyloid-b preparations explain variable outcomes in amyloid-b oligomer toxicity…”
BackgroundPrion protein and Aβ‐related synaptic toxicity impairment
Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., & Aguzzi, A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000082 · Cited by 242 · cited 1×
“While two studies demonstrated amyloid-b triggered impairment of long-term potentiation (LTP) independently of PrPC (Calella et al., 2010; Kessels et al., 2010), it has been suggested that different conformations of amyloid-b preparations explain variable outcomes in amyloid-b oligomer toxicity…”
Ma, T., Chen, Y., Vingtdeux, V., Zhao, H., Viollet, B., Marambaud, P., & Klann, E. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1694-14.2014 · Cited by 191
Giuffrida, R., Musumeci, S., D'Antoni, S., Bonaccorso, C. M., Giuffrida-Stella, A. M., Oostra, B. A., & Catania, M. V. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0932-05.2005 · Cited by 141 · cited 1×
“Similarly, a pathologically reduced association be- tween mGluRs and Homer has been demonstrated in several neurological diseases, including fragile X syndrome and Angelman syndrome (Giuffrida et al., 2005; Pignatelli et al., 2014).”
BackgroundKostylev, M. A., Kaufman, A. C., Nygaard, H. B., Patel, P., Haas, L. T., Gunther, E. C., Vortmeyer, A., & Strittmatter, S. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643577 · Cited by 133 · cited 3×
“PrPlinked immuonosorbent assay PrP-ELISA, which measures PrP-interacting amyloid-b oligomers, has been described previously (Kostylev et al., 2015).”
MethodInfluentialSelf-citationAmyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity
Nicoll, A. J., Panico, S., Freir, D. B., Wright, D., Terry, C., Risse, E., Herron, C. E., O’Malley, T., Wadsworth, J. D. F., Farrow, M. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3416 · Cited by 119
Kiyota, T., Yamamoto, M., Xiong, H., Lambert, M. P., Klein, W. L., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006197 · Cited by 114
Klyubin, I., Nicoll, A. J., Khalili-Shirazi, A., Farmer, M., Canning, S., Mably, A., Linehan, J., Brown, A., Wakeling, M., Brandner, S., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3526-13.2014 · Cited by 74 · cited 4×
“, 2011) and multiple studies support a role for PrP in mediating Alzheimer’s disease-related pathology (Lauren et al., 2009; Chen et al., 2010; Chung et al., 2010; Gimbel et al., 2010; Barry et al., 2011; Bate and Williams, 2011; Freir et al., 2011; Resenberger et al., 2011; Zou et al., 2011; Kudo et al., 2012, 2013;…”
BackgroundInfluential
Cited by
Howard, D. M., Adams, M. J., Shirali, M., Clarke, T.-K., Marioni, R. E., Davies, G., Coleman, J. R. I., Alloza, C., Shen, X., Barbu, M. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03819-3 · Cited by 612
Synaptic Impairment in Alzheimer’s Disease: A Dysregulated Symphony
Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.002 · Cited by 430
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Li, S., & Selkoe, D. J. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15007 · Cited by 263
Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258
Metadata
- Authors
- Haas, L. T., Salazar, S. V., Kostylev, M. A., Um, J. W., Kaufman, A. C., & Strittmatter, S. M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-14
- Volume
- 139
- Issue
- 2
- Pages
- 526-546
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2233987507
- Cited by
- 146
- References
- 29
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.